The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Asthma patients are more likely to have an asthma attack during winter
Subscribe To Our Newsletter & Stay Updated
